¼¼°èÀÇ BCG ¹é½Å ½ÃÀåÀº 2024-2032³â CAGR 5.4%¸¦ ³ªÅ¸³À´Ï´Ù.
ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼ °áÇÙÀÇ ¼¼°èÀû ºÎ´ãÀº BCG ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
WHO¿¡ µû¸£¸é 2022³â °áÇ٠ȯÀÚ ¼ö´Â 1,060¸¸ ¸íÀ¸·Î 2021³â 1,030¸¸ ¸í, 2020³â 1,000¸¸ ¸í¿¡¼ Áõ°¡ÇÑ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¸¶Âù°¡Áö·Î °áÇÙ ¹ßº´·ü(Àα¸ 10¸¸ ¸í´ç ¿¬°£ ½Å±Ô ȯÀÚ ¼ö)Àº 2020-2021³â°ú 2021-2022³â »çÀÌ¿¡ 1.9% Áõ°¡ÇÑ °ÍÀ¸·Î Æò°¡µË´Ï´Ù. ƯÈ÷ °íÀ§Çè Áö¿ª¿¡¼ °áÇ٠ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¤ºÎ¿Í º¸°Ç±â°üÀº ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ ³ë·ÂÀ» °ÈÇϰí ÀÖ½À´Ï´Ù. ¹é½Å Á¢Á¾À» ÅëÇÑ °áÇÙ ¿¹¹æ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ BCG ¹é½Å ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¼ºÀÎ ºÎ¹®Àº 2024-2032³â µ¿¾È ³ôÀº ¸ÅÃâÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼ºÀÎÀÇ BCG ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä´Â °áÇ٠ȯÀÚ Áõ°¡, ÀÇ·á Á¾»çÀÚ ¹× ¸é¿ª·ÂÀÌ ÀúÇÏµÈ »ç¶÷°ú °°Àº °íÀ§Ç豺¿¡ ´ëÇÑ ¿¹¹æÀÇ Çʿ伺 µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ BCG ¹é½ÅÀÌ ¹æ±¤¾Ï Ä¡·á¿¡ »ç¿ëµÉ ¼ö ÀÖ´Ù´Â °¡´É¼ºÀ¸·Î ÀÎÇØ ¼ºÀÎ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °áÇÙ ¿¹¹æ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¹é½Å Á¢Á¾ÀÇ ÀÌÁ¡ÀÌ ¼ºÀÎ ¿¹¹æÁ¢Á¾À» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àü ¼¼°è ¿©Çà°ú À̹ÎÀ¸·Î ÀÎÇØ °áÇÙÀÌ À¯ÇàÇÏ´Â Áö¿ª¿¡ ³ëÃâµÇ´Â ¼ºÀÎÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹¹æÀû Â÷¿ø¿¡¼ ¹é½Å Á¢Á¾À» Àå·ÁÇϰí ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç ³ë·Â°ú º¸°Ç ±â°üÀÇ ±ÇÀå »çÇ×µµ ¼ºÀÎ BCG ¹é½Å Á¢Á¾À» ÃËÁøÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
¹æ±¤¾Ï ºÐ¾ß´Â ºñ±ÙÀ° ħÀ±¼º ¹æ±¤¾Ï(NMIBC) Ä¡·á¿¡ BCG ¹é½ÅÀÇ È¿´ÉÀÌ ÀÔÁõµÊ¿¡ µû¶ó 2024-2032³â BCG ¹é½Å ½ÃÀåÀÇ ÀÀ¿ë Àü¸ÁÀ» ÀÚ±ØÇÒ °¡´É¼ºÀÌ ÀÖÀ¸¸ç, ¾Ï¼¼Æ÷¸¦ °ø°ÝÇÏ´Â ¸é¿ªÃ¼°è¸¦ ÀÚ±ØÇÏ¿© ¾ÏÀÇ Àç¹ß°ú ÁøÇàÀÇ À§ÇèÀ» Å©°Ô ÁÙÀÔ´Ï´Ù. ÀÓ»ó ¿¬±¸¿Í ȯÀÚµéÀÇ Àå±âÀûÀÎ °á°ú°¡ ±× È¿°ú¸¦ ÀÔÁõÇϰí ÀÖÀ¸¸ç, Ç¥ÁØ Ä¡·á ¿É¼ÇÀ¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ¶ÇÇÑ ¹æ±¤¾Ï ¹ßº´·ü Áõ°¡¿Í ºñ¿ë È¿À²ÀûÀÎ ºñ¼ö¼úÀû Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸¿Í ±àÁ¤ÀûÀÎ ÀÓ»ó½ÃÇè °á°ú´Â ¹æ±¤¾Ï¿¡ ´ëÇÑ BCGÀÇ Ä¡·á È¿°ú¸¦ ´õ¿í ÀÔÁõÇϰí ÀÖÀ¸¸ç, ÀÇ·á ÇöÀå¿¡¼ BCGÀÇ ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
ºÏ¹Ì BCG ¹é½Å ½ÃÀåÀº Ãë¾à°èÃþÀÇ °áÇÙ ¹ßº´·ü Áõ°¡¿Í °áÇÙ ¿¹¹æ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó 2032³â±îÁö »ó´çÇÑ ±Ô¸ð ½ÃÀåÀ» Çü¼ºÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ Á¤ºÎÀÇ °·ÂÇÑ Áö¿ø°ú ÀÚ±Ý Áö¿øÀ¸·Î ¹é½ÅÀÇ Á¢±Ù¼º°ú º¸±ÞÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ºñ±ÙħÀ±¼º ¹æ±¤¾Ï Ä¡·á¿¡¼ BCG ¹é½ÅÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾Ï ºÐ¾ß¿¡¼ BCG ¹é½ÅÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ³ôÀº ¼öÁØÀÇ ÀÇ·á ÀÎÇÁ¶ó, źźÇÑ R&D Ȱµ¿, ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °øÁß º¸°Ç Ä·ÆäÀΰú CDC¿Í °°Àº º¸°Ç ±â°üÀÇ ±ÇÀå »çÇ×Àº BCG ¹é½Å Á¢Á¾ÀÇ Á߿伺À» °ÈÇÏ¿© ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
Global BCG Vaccines Market will demonstrate 5.4% CAGR between 2024 and 2032, attributed to the high prevalence of Tuberculosis worldwide. The ongoing global burden of Tuberculosis, particularly in developing countries, fuels the demand for BCG vaccines.
According to WHO, an estimated 10.6 million people contracted TB globally in 2022, up from 10.3 million in 2021 and 10.0 million in 2020, marking a continued reversal of the previously sustained downward trend up to 2020. Similarly, the Tuberculosis incidence rate (new cases per 100,000 population per year) is assessed to have risen by 1.9% between 2020-2021 and 2021-2022. As more people fall ill with TB, especially in high-risk regions, governments and health organizations intensify immunization efforts. This heightened focus on TB prevention through vaccination significantly contributes to the growth of the BCG vaccines market.
The overall BCG vaccines industry is segregated based on age group, application, end-use, and region.
The adults segment will garner appreciable gains throughout 2024-2032. The demand for BCG vaccines among adults is favored by several factors, including the rise in TB cases and the need for protection in high-risk populations, such as healthcare workers and those with weakened immune systems. In addition, the BCG vaccine's potential therapeutic use in bladder cancer treatment has increased its demand among adults. Heightened awareness about TB prevention and the benefits of vaccination further encourage adult immunization. Moreover, global travel and migration expose more adults to TB-endemic regions, prompting vaccination as a preventive measure. Public health initiatives and recommendations by health organizations also play a significant role in driving adult BCG vaccination.
The bladder cancer segment could stimulate the application landscape of the BCG vaccines market over 2024-2032, propelled by the proven efficacy of BCG vaccines in treating non-muscle invasive bladder cancer (NMIBC). BCG therapy significantly reduces the risk of cancer recurrence and progression by stimulating the immune system to attack cancer cells. Clinical studies and long-term patient outcomes support its effectiveness, making it a standard treatment option. Additionally, increasing bladder cancer incidence rates and the need for cost-effective, non-surgical treatment options drive demand. Ongoing research and positive clinical trial results further validate BCG's therapeutic benefits in bladder cancer, encouraging widespread adoption in medical practice.
North America BCG vaccines market will amass a modest valuation by 2032 due to the rising incidence of Tuberculosis among vulnerable populations and increased awareness of TB prevention. Strong government support and funding for immunization programs ensure widespread vaccine availability and distribution. Additionally, the growing recognition of BCG vaccines' role in treating non-muscle invasive bladder cancer drives their adoption in oncology. Advanced healthcare infrastructure, robust research and development activities, and stringent regulatory standards further support market growth. Public health campaigns and recommendations from health organizations like the CDC reinforce the importance of BCG vaccination, contributing to the market expansion.